Testing effectiveness (Phase 2)Not Yet RecruitingNCT07469956
What this trial is testing
Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer
Who this might be right for
Pancreatic Cancer Resectable
Sun Yat-sen University 30